tiprankstipranks
Niagen Bioscience (NAGE)
NASDAQ:NAGE
US Market
NAGE
Niagen Bioscience
RESEARCH TOOLSreports

Niagen Bioscience (NAGE) Earnings Dates, Call Summary & Reports

Compare
501 Followers

Earnings Data

Report Date
May 07, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
0.02
Last Year’s EPS
-0.01
Same Quarter Last Year
Based on 3 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Mar 04, 2025
|
% Change Since: 35.71%
|
Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record revenues, increased cash flow, and improved operational efficiency. However, the company faces challenges in the supply chain and regulatory landscape, necessitating vigilance against market competitors' misleading practices. Overall, the positive financial results and strategic initiatives suggest a promising outlook despite these challenges.
Company Guidance
During the ChromaDex Corporation's Fourth Quarter 2024 earnings call, the company reported record revenues of $29.1 million, marking a 37% year-over-year increase, and net income of $7.2 million for the quarter. For the full year, ChromaDex achieved net revenues of $99.6 million, a 19% growth from the previous year, and net income of $8.6 million. The company generated a positive cash flow of $12.1 million from operations in 2024 and ended the year with $44.7 million in cash and no debt. The e-commerce channel experienced a 30% year-over-year growth with net sales of $17.3 million, while the Niagen ingredient business saw a 96% increase in sales year-over-year. Gross margins improved by 150 basis points to 62.5% in the fourth quarter. For 2025, ChromaDex projects an 18% growth in net sales, with anticipated modest improvements in gross margins. The company also plans to increase R&D and general administrative expenses while maintaining operational efficiency. Additionally, a corporate rebranding is expected to be announced in the coming weeks.
Record-Breaking Revenue and Growth
ChromaDex delivered record revenues of $29.1 million for Q4 2024, a 37% increase year-over-year, and net income of $7.2 million. Full year net revenues were $99.6 million, a 19% growth YOY.
Strong Cash Flow and Financial Position
Generated $12.1 million in positive cash flow from operations in 2024, ended the year with $44.7 million in cash and no debt.
E-commerce and Ingredient Business Growth
E-commerce channel net sales were $17.3 million, a 30% increase YOY. Food grade and pharmaceutical-grade Niagen ingredient business had net sales of $5.3 million, a 96% increase YOY.
Improved Operational Efficiency
Gross margins improved by 150 basis points to 62.5% in Q4 2024, reflecting operational efficiency and a strategic business mix.
Reduction in Expenses
Selling and marketing expenses as a percentage of net sales improved by 90 basis points, and general and administrative expenses decreased by $6.6 million YOY.
Strategic Initiatives and Name Change
ChromaDex plans to announce a company name change to better represent its strategic direction and growth.
---

Niagen Bioscience (NAGE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

NAGE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 07, 20252025 (Q1)
0.02 / -
-0.01
Mar 04, 20252024 (Q4)
0.02 / 0.09
0
Oct 31, 20242024 (Q3)
<0.01 / 0.03
0.005480.00% (+0.02)
Aug 07, 20242024 (Q2)
-0.02 / 0.00
-0.03
May 08, 20242024 (Q1)
-0.02 / -0.01
-0.0366.67% (+0.02)
Mar 06, 20242023 (Q4)
-0.02 / 0.00
-0.02
Nov 08, 20232023 (Q3)
-0.03 / <0.01
-0.01150.00% (+0.01)
Aug 09, 20232023 (Q2)
-0.04 / -0.03
-0.0966.67% (+0.06)
May 10, 20232023 (Q1)
-0.05 / -0.03
-0.1172.73% (+0.08)
Mar 08, 20232022 (Q4)
-0.03 / -0.02
-0.0875.00% (+0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

NAGE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 04, 2025$5.60$8.55+52.68%
Oct 31, 2024$3.49$5.86+67.91%
Aug 07, 2024$2.63$2.88+9.51%
May 08, 2024$3.83$3.52-8.09%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Niagen Bioscience (NAGE) report earnings?
Niagen Bioscience (NAGE) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
    What is Niagen Bioscience (NAGE) earnings time?
    Niagen Bioscience (NAGE) earnings time is at May 07, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is NAGE EPS forecast?
          NAGE EPS forecast for the fiscal quarter 2025 (Q1) is 0.02.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis